The US National Institutes of Health (NIH) is set to launch a public-private partnership, which will bring together health agencies and pharmaceutical companies to accelerate Covid-19 drugs and vaccines.
The Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) partnership aims to create a collaborative framework to prioritise vaccine and drug candidates.
Furthermore, the partners will help manage clinical trials and regulatory processes. Partner assets will be leveraged for rapid response to the ongoing Covid-19 and future pandemics.
Aside from NIH, health agencies participating in ACTIV include the US Food and Drug Administration, Centers for Disease Control and Prevention, Health and Human Services Office of the